TCRX Q1 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$65M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$5M-262.1% margin

Operating Income

-$8M-390.6% margin

Net Income

-$8M-390.3% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+155.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$13M

Stock-Based Comp.

$344,000

Balance Sheet

Total Assets

$141M

Total Liabilities

$31M

Stockholders' Equity

$109M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$5M	-$4M	-23.6%
Operating Income	-$8M	-$6M	-40.5%
Net Income	-$8M	-$6M	-42.9%